ETONEton Pharmaceuticals, Inc.
Pharmaceutical Preparations
- Revenue
- $80M
- 105% YoY
- Operating margin
- -1.1%
- 84% YoY
- EBITDA
- $3M
- 321% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- 1.0×
- $3M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear7% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $22M | $21M | $32M | $39M | $80M | 105% |
| Operating income | −$1M | −$8M | −$1M | −$3M | −$844K | 68% |
| Net income | −$2M | −$9M | −$936K | −$4M | −$5M | 20% |
| Operating cash flow | −$5M | $5M | $7M | $969K | $11M | 986% |
| Capex | $9K | $38K | $0 | $26K | $333K | 1181% |
| Stock-based comp | $3M | $4M | $3M | $3M | $6M | 74% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $229K · 1
- Net
- −$229K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $3M | $7M | — | — |
| FY2024 | $2M | $8M | — | — |
| FY2023 | $2M | $2M | — | — |